Stifel Nicolaus Downgrades Auxilium Pharmaceuticals (AUXL) to Hold

Go back to Stifel Nicolaus Downgrades Auxilium Pharmaceuticals (AUXL) to Hold

RBC Capital Downgrades Auxilium Pharmaceuticals (AUXL) to Sector Perform

September 24, 2014 7:20 AM EDT

RBC Capital downgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Outperform to Sector Perform with a price target of $32.00 (from $28.00). Recently Endo International announced that it has delivered a proposal to acquire all of the outstanding shares of Auxilium Pharmaceuticals, for a per share consideration... More

Auxilium Pharma (AUXL) Says Endo (ENDP) is Not Superior (QLTI)

September 22, 2014 7:02 AM EDT

Auxilium Pharma (NASDAQ: AUXL) announced that its Board of Directors (the "Board") has reviewed the unsolicited, non-binding and conditional proposal from Endo International plc (Nasdaq: ENDP) and, after consulting with its independent financial and legal advisors, has unanimously... More

Goldman Sachs Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral

September 19, 2014 7:29 AM EDT

Goldman Sachs downgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Buy to Neutral.

Analyst Gary Nachman said, "We downgrade AUXL to Neutral from Buy after ENDPs 9/16 offer to acquire AUXL for $28.10/share,... More

UBS Downgrades Auxilium Pharmaceuticals (AUXL) to Neutral

September 19, 2014 7:27 AM EDT

UBS downgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Buy to Neutral.

For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.

Shares of Auxilium Pharmaceuticals closed at $31.12 yesterday.

... More